title: Beneficial effects of rosuvastatin treatment in patients with metabolic syndrome.
abstract: We determined the effect of 6-month rosuvastatin treatment on blood lipids, oxidative parameters, apolipoproteins, high-sensitivity C-reactive protein, lipoprotein(a), homocysteine, and glycated hemoglobin (HbA1c) in patients with metabolic syndrome (MetS). Healthy individuals (men aged >40 years and postmenopausal women) with a body mass index ≥ 30 (n = 100) who fulfilled the National Cholesterol Education Program Adult Treatment Panel III diagnostic criteria for MetS were included. Total cholesterol and low-density lipoprotein cholesterol (LDL-C) levels decreased (P < .0001). The change in LDL 1 to 3 subgroups was significant (P = .0007, P < .0001, and P = .006, respectively). Changes in LDL 4 to 7 subgroups were not significant. There was a beneficial effect on oxidized LDL, fibrinogen, homocysteine, and HbA1c. Rosuvastatin significantly increased high-density lipoprotein levels (P = .0003). The oxidant/antioxidant status and subclinical inflammatory state were also beneficially changed. Rosuvastatin had a significant beneficial effect on atherogenic dyslipidemia as well as on oxidative stress and inflammatory biomarkers in patients with MetS.
authors.affiliation: Department of Cardiology, Istanbul University Institute of Cardiology, Istanbul, Turkey bostancem@yahoo.com.
authors.forename: Cem
authors.initials: C
authors.lastname: Bostan
authors.affiliation: Department of Cardiology, Istanbul University Institute of Cardiology, Istanbul, Turkey.
authors.forename: Ahmet
authors.initials: A
authors.lastname: Yildiz
authors.affiliation: Department of Cardiology, Istanbul University Institute of Cardiology, Istanbul, Turkey.
authors.forename: Alev Arat
authors.initials: AA
authors.lastname: Ozkan
authors.affiliation: Department of Cardiology, Istanbul University Institute of Cardiology, Istanbul, Turkey.
authors.forename: Isil
authors.initials: I
authors.lastname: Uzunhasan
authors.affiliation: Department of Biochemistry, Istanbul University Institute of Cardiology, Istanbul, Turkey.
authors.forename: Aysem
authors.initials: A
authors.lastname: Kaya
authors.affiliation: Department of Cardiology, Istanbul University Institute of Cardiology, Istanbul, Turkey.
authors.forename: Zerrin
authors.initials: Z
authors.lastname: Yigit
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D005464:Fluorobenzenes / Q000627:therapeutic use*; D006442:Glycated Hemoglobin / Q000378:metabolism; D006710:Homocysteine / Q000097:blood; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D018836:Inflammation Mediators / Q000097:blood; D008055:Lipids / Q000097:blood; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects; D011743:Pyrimidines / Q000627:therapeutic use*; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D002097:C-Reactive Protein; D005340:Fibrinogen; D005464:Fluorobenzenes; D006442:Glycated Hemoglobin; D006710:Homocysteine; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D018836:Inflammation Mediators; D008055:Lipids; D011743:Pyrimidines; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides; C517652:hemoglobin A1c protein, human
keywords: cholesterol subgroups; metabolic syndrome; oxidative stress; rosuvastatin